Fischer, Robert J.
van Doremalen, Neeltje http://orcid.org/0000-0003-4368-6359
Adney, Danielle R.
Yinda, Claude Kwe
Port, Julia R.
Holbrook, Myndi G. http://orcid.org/0000-0003-2376-2633
Schulz, Jonathan E.
Williamson, Brandi N.
Thomas, Tina
Barbian, Kent
Anzick, Sarah L.
Ricklefs, Stacy
Smith, Brian J.
Long, Dan
Martens, Craig
Saturday, Greg
de Wit, Emmie http://orcid.org/0000-0002-9763-7758
Gilbert, Sarah C. http://orcid.org/0000-0002-6823-9750
Lambe, Teresa http://orcid.org/0000-0001-7711-897X
Munster, Vincent J. http://orcid.org/0000-0002-2288-3196
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NA)
Article History
Received: 28 June 2021
Accepted: 23 September 2021
First Online: 7 October 2021
Competing interests
: S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture, and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. All other authors declare no competing interests.